Updated:
Aptose Biosciences Inc.
Aptose Biosciences Inc. is a clinical-stage biotech firm developing targeted therapies for blood cancers, including luxeptinib for AML.
Aptose Biosciences Inc.
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is Aptose Biosciences Inc.'s primary investment focus?
Aptose is a biotechnology company, not an investment firm. Its focus is on developing small-molecule kinase inhibitors for hematologic malignancies. Lead programs target acute myeloid leukemia and B-cell lymphomas.
Does Aptose Biosciences Inc. operate as a family office or external capital allocator?
No. Aptose is a publicly traded clinical-stage biotech firm (Nasdaq: APTO), funded through equity offerings and public markets. It does not manage third-party capital or maintain an institutional LP structure.
What are the key clinical assets in Aptose's pipeline?
The lead candidate is luxeptinib, a pan-FLT3/BTK inhibitor in Phase 1/1b trials for AML and B-cell malignancies. A preclinical program targets mutant IDH enzymes. Both were discovered in-house (per the firm's website and SEC filings, 2024).
Where is Aptose headquartered and what is its geographic footprint?
Aptose is based in San Diego, California. Its clinical trials involve sites in the United States, Canada, and Europe. No international offices are disclosed.
What is the capital structure of Aptose Biosciences?
Aptose is funded through public equity offerings, at-the-market programs, and private placements. It had no long-term debt as of the most recent filing. The company uses a standard corporate governance model with a board of directors and no external investment fund.
Who are the key executives at Aptose?
Key executives include William G. Rice (CEO) and Dr. Susanne R. C. Grande (Chief Medical Officer) (per the firm's website, 2025). The board is composed of individuals with pharmaceutical and capital-markets backgrounds.
How does Aptose generate returns for shareholders?
As a development-stage biotech, Aptose does not generate product revenue. Returns depend on successful regulatory approval and commercialization of its drug candidates, or acquisition outcomes. Financial performance is driven by clinical and regulatory milestones.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: